Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 87 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HFA MDI Clear all

Conditions: Heathy Participants
Interventions: Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Allergic Rhinitis
Interventions: Ciclesonide; Drug
Lead sponsor: Covis Pharma S.à.r.l.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Asthma
Interventions: Albuterol Sulfate, Albuterol-Budesonide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 19
States / cities: Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more

Conditions: Asthma
Interventions: epinephrine inhalation aerosol, Placebo; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 33
States / cities: Costa Mesa, California • Los Angeles, California • Mission Viejo, California + 30 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Beclomethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: levalbuterol tartrate HFA inhalation aerosol, placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: Up to 48 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: St. Petersburg, Florida • DeKalb, Illinois • Nicholasville, Kentucky + 12 more

Conditions: Mild Persistent Asthma
Interventions: methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI; Other · Drug
Lead sponsor: Lupin, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 17
States / cities: Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more

Conditions: Mucociliary Clearance
Interventions: HFO-1234ze(E), HFA-134a; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Asthma
Interventions: Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more

Conditions: Asthma
Interventions: FLOVENT (fluticasone propionate) HFA, Placebo HFA; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Huntington Beach, California • Centennial, Colorado • Jacksonville, Florida + 4 more

Conditions: Asthma
Interventions: Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more

Conditions: Asthma
Interventions: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 3
States / cities: Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri

Conditions: COPD, Chronic Obstructive Pulmonary Disease
Interventions: CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 112
States / cities: Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more

Conditions: Asthma, Bronchospasm, Wheezing, Shortness of Breath
Interventions: Epinephrine Inhalation Aerosol, HFA, Epinephrine Inhalation Aerosol; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Exercise-induced Bronchospasm
Interventions: Levalbuterol tartrate HFA MDI, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Denver, Colorado • Burke, Virginia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 55
States / cities: Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more

Conditions: Asthma
Interventions: Albuterol, Placebo, Proventil® HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Huntington Beach, California • Palmdale, California • Paramount, California + 10 more

Conditions: Asthma
Interventions: AS MDI, Proventil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more

Conditions: Persistent Asthma
Interventions: Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 75
States / cities: Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 85
States / cities: Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more

Conditions: Asthma
Interventions: Budesonide HFA, Budesonide CFC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Asthma, Bronchoconstriction
Interventions: Levalbuterol HFA MDI, Racemic Albuterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more

Conditions: Asthma
Interventions: HFA FP MDI; Drug
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

Ventilation and Perfusion in Asthmatics

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

Effect of Steroids on Gene Expression in the Healthy Smokers Lungs

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

Albuterol HFA MDI in Pediatric Participants With Asthma

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

Effect of Age and Device on Delivery of Fluticasone